|
3. Prévention
|
|
|
New medicines 'should prevent not just treat disease' [BBC News]
|
|
|
|
|
|
The
Academy of Medical Sciences says personalised medicines tailored to the
individual present a "great opportunity" to protect health. It says
this is the way public health should go. But critics say the emphasis in
preventing illness must be on lifestyle.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Jimmy Carter says brain cancer is gone following treatment [STAT]
|
|
|
|
|
|
In
general, older people have weaker immune systems than younger ones;
that’s why standard immunizations such as seasonal flu vaccines tend to
be less effective in elderly people than in young adults.But the
opposite may be true in the immune response to melanoma.
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
Rick's Search for Meaning [The Cancer Letter]
|
|
|
|
|
|
Not
only our personal life and our professional life change our
perspectives, but the drugs that come out during this three-year period
of time have really transformed what we’re doing. From a personal
perspective, we underestimate toxicity. Doctors spend only a short time
with patients in exam rooms. They don’t really see the entire spectrum
of toxicities, how long they last, how they impact patients’ lives.
|
|
|
|
|
|
|
Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned [The Cancer Letter]
|
|
|
|
|
|
Mary
died of ovarian cancer Nov. 24. She was 63. Her death and the
three-year struggle that preceded it appears to have launched Rick,
director of the Office of Hematology and Oncology Products in the FDA
Center for Drug Evaluation and Research, into a new career phase, one
where he infuses an advocate’s urgency into his unchallenged power—he’s
the closest thing America has to a cancer czar.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
UK paying less for cancer drugs than other EU countries [PharmaTimes]
|
|
|
|
|
|
A
particular problem noted by the authors is that patient access
discounts on these prices – which are increasingly used to gain approval
in the UK and some other countries – are usually confidential, meaning
that other countries risk overpaying as they can only use the official
undiscounted prices as a benchmark.
|
|
|
|
|
|
|
|
|
5.8 ASH
|
|
|
|
|
5.8.1 ASH - Communiqués
|
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
Novartis keeps its CAR-T lead with positive Phase II data [FierceBiotech]
|
|
|
|
|
|
Novartis
remains in pole position ahead of Juno Therapeutics ($JUNO), Kite
Pharma ($KITE) and others developing CAR-T therapies for blood cancers.
Each has come through with promising clinical results in cancers with
particularly bleak prognoses, but it remains to be seen how readily the
companies can produce cell therapies at commercial scale.
|
|
|
|
|
|
|
|
|
|
|
5.8.5 ASH - Myélome multiple
|
|
|
|
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
